10-Q quarterly report · filed Nov 5, 2026

Fulgent Genetics, Inc. (FLGT) Q3 2026 10-Q Quarterly Report

Short answer

Fulgent Genetics, Inc. (FLGT) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $90M (up 7.5% year over year) with net income of −$13M.

Q3 2026 key financials · XBRL

Revenue
$90M
+7.5% YoY · +5.9% QoQ
Net income
−$13M
−99.0% YoY · +55.5% QoQ
Operating margin
-24.9%
Gross margin
35.3%

Source: XBRL data from the Fulgent Genetics, Inc. (FLGT) Q3 2026 10-Q on SEC EDGAR. USD.

Fulgent Genetics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $90.4M, up $6.3M, or 8% YoY
  • Gross margin 35% vs 42% YoY, operating loss $22.5M vs $15.4M
  • Best segment anatomic pathology: revenue $40.9M, up $14.9M YoY
  • Worst segment precision diagnostics: revenue $41.8M, down $8.9M YoY
  • Cash resources $652.4M, operating cash flow $92.6M, including $112.3M tax refund; stock repurchases $64.1M YTD
  • Outlook: largest-customer revenue decline, billing-transition collection delays, rising clinical-trial spending and gross-margin uncertainty

Risk Factors

  • No material risk-factor changes from 2025 10-K, including no newly added quarterly risk
  • Billing-system transition: processing backlogs and collection delays may reduce collections, gross margin, liquidity, and results
  • Legal investigations and audits: unfavorable outcomes remain uncertain, with potential defense costs, settlements, management diversion, and reputational harm
  • Largest-customer concentration: customer insourcing continues reducing precision-diagnostics revenue during 2026
  • Liquidity dependence: $112.3 million IRS refund drove operating cash flow, while excluding it operations used approximately $19.8 million

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Fulgent Genetics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.